Are the new migraine medications working?
Three new medications—erenumab (Aimovig), fremanezumab (Ajovy), and galcanezumab (Emgality)—appear to be helping people with frequent, debilitating migraine headaches. Studies suggest that people taking the new drugs experience about 50% fewer migraine headache days per month, compared with people who aren’t taking the medications. However, clinical trials for the new medications have included relatively few older adults, so it’s not known if older adults might react differently to the medications than younger people. Doctors urge older adults to start out taking the lowest dose possible.
To continue reading this article, you must log in.
Source matters. Subscribe to HarvardHealthOnline+ FREE for 30 days for unlimited access to the site – where all content is reviewed by an HMS physician or faculty expert.
With HHO+ you get these exclusive benefits:
- Unlimited access to all Harvard Health Online content
- 4 expertly curated newsletters delivered monthly
- Customized website experience aligned to your health goals
- In-depth health guides on topics like sleep, exercise, and more
- Interactive features like videos and quizzes
- Members-only access to exclusive articles and resources
SPECIAL OFFER! UNLOCK EXPERT ACCESS for 30 days FREE!
Already a member? Login ».
Disclaimer:
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.
